Ipamorelin: Clinical Guide for Prescribing Practices
Ipamorelin is a selective growth hormone secretagogue that stimulates GH release through the ghrelin receptor without significantly affecting cortisol, prolactin, or ACTH levels. It is one of the most selective GHRPs available, making it a preferred choice for GH optimization with minimal side effects.
Also Known As
How Ipamorelin Works
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that selectively activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor targeted by endogenous ghrelin [1]. Unlike other GHRPs, ipamorelin does not significantly activate ACTH or cortisol release pathways, nor does it stimulate prolactin secretion [2]. This selectivity results from its specific binding kinetics that favor GH release signaling over other neuroendocrine axes, making it the cleanest GH secretagogue available [1].
Clinical Evidence
Phase II clinical trials demonstrated that ipamorelin produces dose-dependent GH release comparable to GHRP-6 but without the cortisol, ACTH, or prolactin elevations seen with less selective secretagogues [1]. Studies in post-surgical patients showed accelerated recovery of bowel function, suggesting tissue-repair applications beyond GH optimization [3]. The selectivity profile has been confirmed across multiple dose ranges in healthy volunteers, establishing ipamorelin as the reference standard for selective GH secretion [4].
Clinical Uses
Patient Selection and Screening
Ideal for patients who desire GH optimization but are sensitive to hormonal fluctuations, have anxiety-related concerns about cortisol elevation, or have experienced side effects with less selective GHRPs [1][2]. Also appropriate for female patients where prolactin elevation is undesirable. Best candidates have intact pituitary function with low-normal IGF-1. Contraindications include active malignancy, pregnancy, and uncontrolled diabetes. Screen with baseline IGF-1, prolactin, cortisol, and metabolic panel.
Dosing and Administration
Standard dosing is 200 to 300mcg subcutaneously, administered 1 to 3 times daily (most commonly once at bedtime or twice daily: morning and bedtime) [4]. Administer on an empty stomach (no caloric intake for 30 minutes before or after injection) for optimal GH release. Most effective when combined with a GHRH analog (CJC-1295 at 100 to 200mcg or sermorelin at 200 to 300mcg) at the same injection time [1]. Continuous daily use is generally well-tolerated without significant desensitization, though some protocols cycle 5 days on/2 days off. All dosing decisions require physician clinical judgment.
Route: Subcutaneous injection
Protocol notes: Administered via subcutaneous injection, typically 200-300mcg 2-3 times daily or before bedtime. Often combined with a GHRH analog for synergistic effect.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Ipamorelin is most commonly sold as part of a combination protocol with CJC-1295, which commands higher program pricing than standalone ipamorelin [1]. Standalone ipamorelin wholesale costs range from $30 to $50 per vial. Practices using ipamorelin as a solo agent typically price at $150 to $300 per month, while the CJC-1295/Ipamorelin combination commands $250 to $500 per month. The selectivity and tolerability profile makes it excellent for patient retention and satisfaction scores [2].
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe Ipamorelin through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
Why is ipamorelin preferred over other GH secretagogues?
Is standalone ipamorelin effective or does it need to be combined?
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561
- Jimenez-Reina L et al. Selectivity of ipamorelin as a growth hormone secretagogue. Growth Horm IGF Res. 2002;12(1):49-57
- Greenwood-Van Meerveld B et al. Ipamorelin improves postoperative ileus. J Pharmacol Exp Ther. 2007;320(3):1094-1101
- Hansen TK et al. Dose-dependent pharmacokinetics and pharmacodynamics of ipamorelin. Eur J Endocrinol. 1999;141:580-588
Related Peptides in Growth Hormone Support
CJC-1295/Ipamorelin
Growth Hormone Support
View Guide →
AOD-9604
Growth Hormone Support
View Guide →
Tesamorelin
Growth Hormone Support
View Guide →
Sermorelin
Growth Hormone Support
View Guide →
MK-677
Growth Hormone Support
View Guide →
GHRP-2
Growth Hormone Support
View Guide →
GHRP-6
Growth Hormone Support
View Guide →
Hexarelin
Growth Hormone Support
View Guide →
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe Ipamorelin Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe Ipamorelin Through Karpa